A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia

Trial Profile

A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs ACP 01 (Primary)
  • Indications Peripheral ischaemia
  • Focus Therapeutic Use
  • Sponsors Hemostemix
  • Most Recent Events

    • 19 Apr 2018 According to a Hemostemix Inc. media release, the FDA has approved the IND for ACP-01, and company will be enrolling subjects at 15-20 clinical trial sites in Canada and the United States over the next 6 months.
    • 20 Dec 2017 According to a Hemostemix Inc. media release, the company has received a No Objection Letter from Health Canada for trials of ACP-01 for patients with critical limb ischemia.
    • 06 Dec 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top